- In May 2024, The FDA provided comprehensive updates on Zika virus response efforts, detailing the virus's transmission, symptoms, and associated risks, particularly for pregnant women. Key highlights included the lack of FDA-approved vaccines and treatments, though several diagnostic tests have received Emergency Use Authorization. Further, recent determinations indicated that Zika is no longer a relevant transfusion-transmitted infection, allowing blood establishments to adjust screening protocols. The FDA emphasizes ongoing collaboration with public health authorities to ensure safety and effective responses to Zika outbreaks.
